Health
US FDA warns of counterfeit versions of Novo’s diabetes drug Ozempic
The US Food and Drug Administration has warned consumers not to use counterfeit versions of Novo Nordisk’s diabetes drug Ozempic, which have been found in
The JN.1 variant accounts for 39-50% of COVID cases in the US
The US Food and Drug Administration has warned consumers not to use counterfeit versions of Novo Nordisk’s diabetes drug Ozempic, which have been found in
The JN.1 variant accounts for 39-50% of COVID cases in the US
The US Centers for Disease Control and Prevention said the agency projected that COVID subvariant JN.1 accounted for 39% to 50% of cases in the
FDA warns against counterfeit Ozempic
The US Food and Drug Administration warned consumers not to use counterfeit versions of Novo Nordisk’s diabetes drug Ozempic that have been found in the
Jazz Pharmaceuticals PTSD drug fails in mid-stage trial
Jazz Pharmaceuticals said its post-traumatic stress disorder (PTSD) drug failed to meet its primary endpoint in a mid-stage study. The drugmaker said it does not
US FDA approves Ionis-AstraZeneca drug for nerve disease
The US Food and Drug Administration (FDA) has approved a drug from Ionis Pharmaceuticals and its partner AstraZeneca to treat nerve damage caused by a
US FDA refused to approve Merck’s chronic cough drug
The US Food and Drug Administration has refused to approve Merck’s drug for the treatment of chronic cough. The health regulator concluded that the company’s
Sanofi discontinues cancer research programme to evaluate tusamitamab ravtansine
French healthcare company Sanofi on Thursday said it was ending a programme to evaluate tusamitamab ravtansine linked to the treatment of various types of lung
US FDA approves first test to detect risk of addiction to opioids
The US Food and Drug Administration said it has approved the first test to assess whether certain people are at risk of addiction to opioids.
WHO states that the JN.1 COVID strain is a “variant of interest” and poses a low risk
The World Health Organisation has classified the JN.1 coronavirus strain as a “variant of interest” and said current data show that the public health risk